The Food and Drug Administration recently approved esketamine — in nasal spray form — to help treat major depression. And another fast-acting drug for post-partum depression has also been approved, one that's administered via an IV.
We’re seeing a period in which a new class of anti-depression drugs known as NMDAs is being introduced — following SSRIs in the 1970s and SNRIs in the 1990s.
To learn more about the impact of NMDAs and esketamine, The Show was joined by Michael Thase, a psychiatry professor at the University of Pennsylvania. He’s also received financial support from Janssen for research on esketamine.
